Note 16 - Segments (Tables)

6 Months Ended

Jun. 30, 2017

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

T hree Months Ended June 30, 2017	Diagnostics			Therapeutics			Corporate			Total
Tc 99m tilmanocept sales revenue:
United States	$	—		$	—		$	—		$	—
International		—			—			—			—
Tc 99m tilmanocept license revenue		100,000			—			—			100,000
Grant and other revenue		418,375			93,224			—			511,599
Total revenue		518,375			93,224			—			611,599
Cost of goods sold, excluding depreciation and amortization		—			—			—			—
Research and development expenses, excluding depreciation and amortization		1,108,101			77,773			—			1,185,874
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			3,462			4,175,583			4,179,045
Depreciation and amortization (2)		—			—			70,539			70,539
Income (loss) from operations (3)		(589,726	)		11,989			(4,246,122	)		(4,823,859	)
Other income		—			—			40,848			40,848
Income tax benefit (expense)		201,125			(4,089	)		1,434,198			1,631,234
Net income (loss) from continuing operations		(388,601	)		7,900			(2,771,076	)		(3,151,777	)
Loss from discontinued operations, net of tax		(82,376	)		—			—			(82,376	)
Loss on sale of discontinued operations, net of tax		(1,953,378	)		—			—			(1,953,378	)
Net income (loss)		(2,424,355	)		7,900			(2,771,076	)		(5,187,531	)
Total assets, net of depreciation and amortization:
United States		16,373,919			16,002			9,411,189			25,801,110
International		98,806			—			2,299			101,105
Capital expenditures		—			—			8,170			8,170

Three Months Ended June 30 , 2016	Diagnostics			Therapeutics			Corporate			Total
Tc 99m tilmanocept sales revenue:
United States	$	—		$	—		$	—		$	—
International		4,399			—			—			4,399
Tc 99m tilmanocept license revenue		245,950			—			—			245,950
Grant and other revenue		865,359			51,452			—			916,811
Total revenue		1,115,708			51,452			—			1,167,160
Cost of goods sold, excluding depreciation and amortization		807			—			—			807
Research and development expenses, excluding depreciation and amortization		1,907,885			111,326			—			2,019,211
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			4,430			1,289,203			1,293,633
Depreciation and amortization (2)		—			—			94,184			94,184
Loss from operations (3)		(792,984	)		(64,304	)		(1,383,387	)		(2,240,675	)
Other income, excluding equity in loss of R-NAV, LLC (4)		—			—			1,427,078			1,427,078
Equity in loss of R-NAV, LLC		—			—			(2,920	)		(2,920	)
Net income (loss) from continuing operations		(792,984	)		(64,304	)		40,771			(816,517	)
Loss from discontinued operations, net of tax		(5,864,790	)		—			—			(5,864,790	)
Net income (loss)		(6,657,774	)		(64,304	)		40,771			(6,681,307	)
Total assets, net of depreciation and amortization:
United States		4,774,933			36,841			3,548,425			8,360,199
International		321,359			—			591			321,950
Capital expenditures		—			—			1,847			1,847

Six Months Ended June 30, 2017	Diagnostics			Therapeutics			Corporate			Total
Tc 99m tilmanocept sales revenue:
United States	$	—		$	—		$	—		$	—
International		—			—			—			—
Tc 99m tilmanocept license revenue		100,000			—			—			100,000
Grant and other revenue		989,737			101,892			—			1,091,629
Total revenue		1,089,737			101,892			—			1,191,629
Cost of goods sold, excluding depreciation and amortization		—			—			—			—
Research and development expenses, excluding depreciation and amortization		1,521,303			369,845			—			1,891,148
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			5,983			7,118,706			7,124,689
Depreciation and amortization (2)		—			—			147,329			147,329
Loss from operations (3)		(431,566	)		(273,936	)		(7,266,035	)		(7,971,537	)
Other expense		—			—			(1,130,261	)		(1,130,261	)
Income tax benefit		146,296			92,861			2,846,249			3,085,406
Net loss from continuing operations		(285,270	)		(181,075	)		(5,550,047	)		(6,016,392	)
Loss from discontinued operations, net of tax		(338,237	)		—			—			(338,237	)
Gain on sale of discontinued operations, net of tax		86,748,123			—			—			86,748,123
Net income (loss)		86,124,616			(181,075	)		(5,550,047	)		80,393,494
Total assets, net of depreciation and amortization:
United States		16,373,919			16,002			9,411,189			25,801,110
International		98,806			—			2,299			101,105
Capital expenditures		—			—			8,170			8,170

Six Months Ended June 30 , 2016	Diagnostics			Therapeutics			Corporate			Total
Tc 99m tilmanocept sales revenue:
United States	$	—		$	—		$	—		$	—
International		13,199			—			—			13,199
Tc 99m tilmanocept license revenue		500,000			—			—			500,000
Grant and other revenue		1,550,994			51,452			—			1,602,446
Total revenue		2,064,193			51,452			—			2,115,645
Cost of goods sold, excluding depreciation and amortization		2,296			—			—			2,296
Research and development expenses, excluding depreciation and amortization		3,738,356			353,126			—			4,091,482
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			3,832			3,847,961			3,851,793
Depreciation and amortization (2)		—			—			169,150			169,150
Loss from operations (3)		(1,676,459	)		(305,506	)		(4,017,111	)		(5,999,076	)
Other income, excluding equity in loss of R-NAV, LLC (4)		—			—			2,515,902			2,515,902
Equity in loss of R-NAV, LLC		—			—			(15,159	)		(15,159	)
Net loss from continuing operations		(1,676,459	)		(305,506	)		(1,516,368	)		(3,498,333	)
Loss from discontinued operations, net of tax		(6,869,223	)		—			—			(6,869,223	)
Net loss		(8,545,682	)		(305,506	)		(1,516,368	)		(10,367,556	)
Total assets, net of depreciation and amortization:
United States		4,774,933			36,841			3,548,425			8,360,199
International		321,359			—			591			321,950
Capital expenditures		—			—			1,847			1,847